Hisun has initiated the risk assessment of the product regarding Nitrosamine genetic toxic impurities in accordance with EMA guidelines. The risk assessment of the product Cyclophysphamide is expected to be completed by the end of December 2019. Once completing the risk assessment, Hisun will inform you about the assessment conclusion.